{"disease":{"id":"advanced-tumours","name":"advanced tumours"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06304818","title":"Aims to Explore the Safety, Tolerability, and Preliminary Efficacy of SCTB14 in Adult Patients With Advanced Malignant Solid Tumours.","phase":"PHASE1, PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":515,"lead_sponsor_name":"Sinocelltech Ltd.","has_results":false},{"nct_id":"NCT06600022","title":"Aims to Explore the Safety, Tolerability, and Preliminary Efficacy of SCTB41 in Adult Patients with Advanced Malignant Solid Tumours.","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":441,"lead_sponsor_name":"Sinocelltech Ltd.","has_results":false},{"nct_id":"NCT05647122","title":"First in Human Study of AZD9592 in Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":403,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT06888830","title":"A Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Initial Efficacy of JS212 in Subjects With Advanced Malignant Solid Tumour","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":374,"lead_sponsor_name":"Shanghai Junshi Bioscience Co., Ltd.","has_results":false},{"nct_id":"NCT01078662","title":"Open Label Study to Assess Efficacy and Safety of Olaparib in Confirmed Genetic BRCA1 or BRCA2 Mutation Pats","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":298,"lead_sponsor_name":"AstraZeneca","has_results":true},{"nct_id":"NCT06795412","title":"Phase 1/2 Study of PYX-201 in Combination With Pembrolizumab in Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":220,"lead_sponsor_name":"Pyxis Oncology, Inc","has_results":false},{"nct_id":"NCT07306559","title":"A Study to Test How Well Different Doses of BI 3820768 Are Tolerated by People With Advanced Cancer (Solid Tumours)","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":187,"lead_sponsor_name":"Boehringer Ingelheim","has_results":false},{"nct_id":"NCT05154604","title":"A Study of SHR-A1921 for Injection in Subjects With Advanced Solid Tumours","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":156,"lead_sponsor_name":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","has_results":false},{"nct_id":"NCT02879162","title":"Durvalumab and Tremelimumab in Patients With Advanced Rare Tumours","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":140,"lead_sponsor_name":"Canadian Cancer Trials Group","has_results":true},{"nct_id":"NCT01396408","title":"A Phase II Study of Sunitinib or Temsirolimus in Patients With Advanced Rare Tumours","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":137,"lead_sponsor_name":"Canadian Cancer Trials Group","has_results":false},{"nct_id":"NCT04999969","title":"Safety, Pharmacokinetics and Clinical Activity of AZD0171 in Combination With Durvalumab and Chemotherapy in Locally Advanced or Metastatic Solid Tumours","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":126,"lead_sponsor_name":"AstraZeneca","has_results":true},{"nct_id":"NCT03518606","title":"Metronomic Oral Vinorelbine Plus Anti-PD-L1/Anti-CTLA4 ImmunothErapy in Patients With Advanced Solid Tumours","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":126,"lead_sponsor_name":"UNICANCER","has_results":false},{"nct_id":"NCT05701527","title":"A Study of EBC-129 in Advanced Solid Tumours","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":98,"lead_sponsor_name":"EDDC (Experimental Drug Development Centre), A*STAR Research Entities","has_results":false},{"nct_id":"NCT06868199","title":"A Study of LM-168 as a Single Agent or in Combination With Toripalimab in Subjects With Advanced Solid Tumours","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":87,"lead_sponsor_name":"LaNova Medicines Limited","has_results":false},{"nct_id":"NCT02588105","title":"Study to Assess the Safety and Preliminary Efficacy of AZD0156 at Increasing Doses Alone or in Combination With Other Anti-cancer Treatment in Patients With Advanced Cancer","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":84,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT02389842","title":"PIPA: Combination of PI3 Kinase Inhibitors and PAlbociclib","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":79,"lead_sponsor_name":"Royal Marsden NHS Foundation Trust","has_results":false},{"nct_id":"NCT03746431","title":"A Phase 1 Study of [225Ac]-FPI-1434 Injection","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":78,"lead_sponsor_name":"Fusion Pharmaceuticals Inc.","has_results":false},{"nct_id":"NCT03421353","title":"AZD9150 Plus Durvalumab Alone or in Combination With Chemotherapy in Patients With Advanced, Solid Tumours and in Patients With Non-Small-Cell Lung Cancer","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":76,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT02579226","title":"A Phase I Study of Safety, Tolerability, and PK of AZD2811 in Patients With Advanced Solid Tumors.","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":72,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT03486730","title":"BT1718 in Patients with Advanced Solid Tumours.","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":72,"lead_sponsor_name":"Cancer Research UK","has_results":false},{"nct_id":"NCT04839991","title":"Study of CB307 in Patients With Advanced and/or Metastatic PSMA-positive Tumours.","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":70,"lead_sponsor_name":"Crescendo Biologics Ltd.","has_results":false},{"nct_id":"NCT06927349","title":"A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of BA1301 in Advanced Solid Tumors.","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":70,"lead_sponsor_name":"Shandong Boan Biotechnology Co., Ltd","has_results":false},{"nct_id":"NCT05021120","title":"A Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of AK127 in Combination With AK104 in Advanced and Metastatic Solid Tumours","phase":"EARLY_PHASE1","overall_status":"COMPLETED","enrollment_count":67,"lead_sponsor_name":"Akesobio Australia Pty Ltd","has_results":false},{"nct_id":"NCT02610075","title":"Phase Ib Study to Determine MTD of AZD1775 Monotherapy in Patients With Locally Advanced or Metastatic Solid Tumours.","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":62,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT04504669","title":"First Time in Human Study of AZD8701 With or Without Durvalumab in Participants With Advanced Solid Tumours","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":60,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT04434482","title":"IMP4297 in Combination With Temozolomide in Patients With Advanced Solid Tumors and Small Cell Lung Cancer","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":59,"lead_sponsor_name":"Impact Therapeutics, Inc.","has_results":false},{"nct_id":"NCT03508011","title":"A Study of IMP4297 in Patients With Advanced Solid Tumors","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":57,"lead_sponsor_name":"Impact Therapeutics, Inc.","has_results":false},{"nct_id":"NCT02617277","title":"Safety, Tolerability and Pharmacokinetics of AZD1775 (Adavosertib) Plus MEDI4736 (Durvalumab) in Patients With Advanced Solid Tumours","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":56,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT02285816","title":"MG1 Maraba/MAGE-A3, With and Without Adenovirus Vaccine With Transgenic MAGE-A3 Insertion in Incurable MAGE-A3-Expressing Solid Tumours","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":56,"lead_sponsor_name":"Canadian Cancer Trials Group","has_results":false},{"nct_id":"NCT04564027","title":"A Study Investigating DNA-damage Response Agents in Molecularly Altered Advanced Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":54,"lead_sponsor_name":"AstraZeneca","has_results":true},{"nct_id":"NCT06815575","title":"A Safety and Pharmacokinetics Study of RC220 Combined With Doxorubicin in Adult Participants With Solid Tumours.","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":53,"lead_sponsor_name":"Race Oncology Ltd","has_results":false},{"nct_id":"NCT04907851","title":"A Study to Assess RXC004 Efficacy in Advanced Solid Tumours After Progression on Standard of Care (SoC) Therapy (PORCUPINE2)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":45,"lead_sponsor_name":"Redx Pharma Ltd","has_results":true},{"nct_id":"NCT03548467","title":"A Study to Evaluate Safety and Efficacy of Multiple Dosing With VB10.NEO and Bempegaldesleukin (NKTR-214) Immunotherapy in Patients With Locally Advanced or Metastatic Cancer","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":41,"lead_sponsor_name":"Nykode Therapeutics ASA","has_results":false},{"nct_id":"NCT05508334","title":"A Study to Assess the Safety and Tolerability of RC88 for Patients With Advanced Solid Tumours","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":41,"lead_sponsor_name":"RemeGen Co., Ltd.","has_results":false},{"nct_id":"NCT03507543","title":"The Safety and Pharmacokinetics of IMP4297 in Patients With Advanced Solid Tumors","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":39,"lead_sponsor_name":"Impact Therapeutics, Inc.","has_results":false},{"nct_id":"NCT02430311","title":"The Pharmacokinetics and Safety of Olaparib Alone and With Paclitaxel in Chinese Patients With Advanced Solid Tumour.","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":36,"lead_sponsor_name":"AstraZeneca","has_results":true},{"nct_id":"NCT05537051","title":"A Study of PM1021 (Anti-TIGIT) With or Without PM8001 (Anti-PD-L1/TGF-β) in Patients With Advanced Solid Tumours","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":30,"lead_sponsor_name":"Biotheus Inc.","has_results":false},{"nct_id":"NCT05644392","title":"A Study Evaluating Cadonilimab Injection in Combination With Regorafenib for the Treatment of Biliary Systemic Tumours","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":30,"lead_sponsor_name":"Tianjin Medical University Cancer Institute and Hospital","has_results":false},{"nct_id":"NCT03101839","title":"Phase I Dose-Escalation Study of AZD4785 in Patients With Advanced Solid Tumours","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":28,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT02341456","title":"Phase Ib Study AZD1775 in Combination With Carboplatin and Paclitaxel in Adult Asian Patients With Solid Tumours","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":19,"lead_sponsor_name":"AstraZeneca","has_results":true},{"nct_id":"NCT04882176","title":"A Clinical Study Preliminary Efficacy of LM-061 Tablet in Subjects With Advanced Tumours","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":18,"lead_sponsor_name":"LaNova Medicines Limited","has_results":false},{"nct_id":"NCT04737122","title":"Study of LM-061 in Subjects in Advanced Tumors","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":18,"lead_sponsor_name":"LaNova Medicines Limited","has_results":false},{"nct_id":"NCT03150368","title":"Extended Use of ModraDoc006/r","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":17,"lead_sponsor_name":"Modra Pharmaceuticals","has_results":false},{"nct_id":"NCT06599502","title":"A Phase I/IIa Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD0022 as Monotherapy and in Combination With Anti-cancer Agents in Adult Participants With Tumours Harbouring a KRASG12D Mutation","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":17,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT04742036","title":"Capivasertib China PK Study","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":16,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT06929195","title":"Clinical Trial to Evaluate the Tolerance of TQB2210 Injection","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":16,"lead_sponsor_name":"Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT03525392","title":"Study to Evaluate the Safety and Activity (Including Distribution) of 177Lu-3BP-227 in Subjects With Solid Tumours Expressing Neurotensin Receptor Type 1.","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":14,"lead_sponsor_name":"Ipsen","has_results":true},{"nct_id":"NCT05514132","title":"A Study to Evaluate the Safety and Pharmacokinetics of Ceralasertib in Combination With Durvalumab in Chinese Patients With Advanced Solid Tumours","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":14,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT04462952","title":"Study of Adavosertib(AZD1775) in Japanese Patients With Advanced Solid Tumours","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":6,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT05920408","title":"Study to Assess EXS21546 in Combination in Patients With Advanced Solid Tumours","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":6,"lead_sponsor_name":"Exscientia AI Limited","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}